EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Horizon scan of the clinical development landscape of biosimilar products in the UK and EU

Amy Hussain, Ross Fairbairn iD, Sarah Khalid Khan iD

International Journal of Technology Assessment in Health Care · 2026

DOI: 10.1017/s0266462326103468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2026. Verfasst von Amy Hussain und 2 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Drug Development. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Biosimilars are biological medicines highly similar to an authorized reference medicine, offering substantial cost savings and increased treatment access. Despite the regulatory framework in the UK and EU facilitating their approval, the biosimilar landscape remains small compared to small-molecule drugs. This study provides a horizon scanning overview of the current biosimilar landscape, procured through horizon scanning activities.

Methods

Data were sourced from ClinicalTrials.gov and the EU Clinical Trials Register, scanned monthly to identify innovative medicines in clinical development. We included biosimilars identified through horizon scanning from April 2017 to February 2025. Supplementary data were collected from the European Medicines Agency to ascertain approval status, and additional clinical trial information was manually extracted from relevant registries.

Results

We identified 156 unique biosimilars developed across 174 clinical trials, with sixty-four approved by the MHRA and seventy-eight by the European Medicines Agency. Adalimumab, bevacizumab, and denosumab were the reference products with the most biosimilars in development. Most biosimilar trials were at phase III. There are seventy-one biosimilars in active development.

Conclusions

The development landscape of biosimilars in the UK and EU show high activity levels. Continuous improvements in horizon scanning methods and regulatory frameworks are essential to support the timely adoption of biosimilars, maximizing their benefits for healthcare systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsDrug DevelopmentUnited KingdomHumansEuropean UnionDrug ApprovalClinical Trials as Topic

Stichwörter der Autor:innen

biosimilarsemerging technologieshorizon scanningmedicinespharmaceutical innovation

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Population Health Sciences Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK.

ORCID-Profile: Ross Fairbairn, Sarah Khalid Khan

Förderung

  • National Institute for Health and Care Research

Zitieren

APA

Hussain, A., Fairbairn, R., & Khan, S. K. (2026). Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462326103468

Vancouver

Hussain A, Fairbairn R, Khan SK. Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. International Journal of Technology Assessment in Health Care. 2026. doi:10.1017/s0266462326103468

BibTeX
@article{Hussain2026,
  author = {Hussain, Amy and Fairbairn, Ross and Khan, Sarah Khalid},
  title = {Horizon scan of the clinical development landscape of biosimilar products in the UK and EU},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2026},
  doi = {10.1017/s0266462326103468}
}
Kostenlos starten →